

Announcement No. 5/2012
7 May 2012**Revised financial calendar for 2011/12**

The silent periods before the financial statements for Q3 and Full Year 2011/12 respectively have been extended – see table below.

2011

- 12.10. Closing period until 1 November
- 25.10. Notice of submission of agenda points for the Annual General Meeting
- 1.11. Financial Statements for the full year 2010/11
Annual Report 2010/11
- 7.12. Annual General Meeting
- 13.12. Dividends for 2010/11 at the disposal of shareholders

2012

- 6.1. Closing period until 25 January
- 25.1. Interim Financial Statements for Q1 2011/12
- 5.4. Closing period until 26 April
- 26.4. Interim Financial Statements for H1 2011/12
- 9.7. Closing period until 15 August
- 15.8. Interim Financial Statements for 9M 2011/12
- 10.10. Closing period until 6 November
- 30.10. Notice of submission of agenda points for the Annual General Meeting
- 6.11. Financial Statements for the full year 2011/12
Annual Report 2011/12
- 11.12. Annual General Meeting
- 17.12. Dividends for 2011/12 at the disposal of shareholders

For further information, please contact

Investors and analysts

Lene Skole
Executive Vice President, CFO
Tel. +45 4911 1700

Ian S.E. Christensen
Vice President, Investor Relations
Tel. +45 4911 1800/+45 4911 1301
Email: dkisec@coloplast.com

Henrik Nord
Investor Relations Manager
Tel. +45 4911 1800/+45 4911 3108
Email: dkhno@coloplast.com

Press and the media

Ulla Lundhus
Media Relations Manager
Tel. +45 4911 1929
Email: dkul@coloplast.com

This announcement is available in a Danish and an English-language version.
In the event of discrepancies, the Danish version shall prevail.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2012-5 All rights reserved. Coloplast A/S, 3050 Humlebæk, Denmark.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Urology Care, Continence Care and Wound and Skin Care. We operate globally and employ around 7,500 people.